DEA Administrator Sidesteps Marijuana Rescheduling Decision

DEA Administrator Sidesteps Marijuana Rescheduling Decision

In a recent development that has stirred the pot in drug policy circles, sources within the Drug Enforcement Administration (DEA) have disclosed that DEA Administrator Anne Milgram did not approve the decision to reschedule marijuana. This revelation, highlighted by Dr. Kevin Sabet, a prominent figure in drug policy reform, underscores a significant deviation from longstanding procedural norms. The decision to shift marijuana from Schedule I to Schedule III classification, while still proceeding, marks a contentious moment within the DEA and broader administration. Dr. Rachel Levine of the Department of Health and Human Services had signed off on the recommendation, which then moved to the DEA for review, adhering to the Controlled Substances Act’s stipulation that the Attorney General holds the final scheduling authority, delegated in this instance to the DEA Administrator.

This move has sparked debate on the motivations and implications behind the rescheduling process, with critics pointing to political influences overshadowing scientific and legal considerations. Anne Milgram’s notable abstention from signing the rescheduling order has been both criticised and praised, reflecting the deep divisions over marijuana policy in the United States. Milgram is expected to face scrutiny from lawmakers during an upcoming hearing with the House Committee on Appropriations, where the DEA’s Fiscal Year 2025 funding and the marijuana rescheduling decision will be key topics of discussion.

For more insights into this unfolding story, visit The Drug Report.

Leave a Reply

Your email address will not be published.